FibroGen (FGEN) PT Lowered to $16 at Goldman Sachs, After Receiving CRL from FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts FGEN Hot Sheet
Price: $9.71 --0%
Rating Summary:
4 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
4 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi lowered the price target on FibroGen (NASDAQ: FGEN) to $16.00 (from $22.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- Regeneron Pharma (REGN) PT Raised to $875 at Baird
- Freedom Broker Downgrades RPC Inc. (RES) to Sell
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
